Prevention of myocardial infarction and stroke by aspirin: Different mechanisms? Different dosage?

Thrombosis Research

Volumn 92, Issue 1 SUPPL. 1, 1998, Pages

  Patrono, Carlo ^a  

^a UNIVERSITY OF CHIETI   (Italy)

Author keywords

Aspirin; Clopidogrel; Dipyridamole; Myocardial infarction; Stroke; Ticlopidine

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; CLOPIDOGREL; DIPYRIDAMOLE;

CLINICAL ARTICLE; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED STUDY; CORONARY ARTERY THROMBOSIS; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; HEART INFARCTION; HUMAN; OCCLUSIVE CEREBROVASCULAR DISEASE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STROKE; TRANSIENT ISCHEMIC ATTACK; TREATMENT OUTCOME;

ASPIRIN; CEREBROVASCULAR DISORDERS; FIBRINOLYTIC AGENTS; HUMANS; MYOCARDIAL INFARCTION; MYOCARDIAL ISCHEMIA; PLATELET AGGREGATION INHIBITORS; RANDOMIZED CONTROLLED TRIALS;

EID: 0032531116     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0049-3848(98)00101-7     Document Type: Conference Paper

References (40)

1. Patrono C. Aspirin as an antiplatelet drug. N Engl J Med. 30:1994;1287-1294.
2. Antiplatelet Trialists' Collaboration Collaborative overview of randomised trials of antiplatelet therapy - I. Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients BMJ. 308:1994;81-106.
3. Vane J.R. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nature New Biol. 231:1971;232-235.
4. Roth G.J., Stanford N., Majerus P.W. Acetylation of prostaglandin synthase by aspirin. Proc Natl Acad Sci USA. 72:1975;3073-3076.
5. Patrono C., Ciabattoni G., Pinca E., Pugliese F., Castrucci G., De Salvo A., Satta M.A., Peskar B.A. Low dose aspirin and inhibition of thromboxane B2 production in healthy subjects. Thromb Res. 17:1980;317-327.
6. Patrignani P., Filabozzi P. Patrono C. Selective cumulative inhibition of thromboxane production by low-dose aspirin in healthy subjects. J Clin Invest. 69:1982;1366-1372.
7. Weksler B.B., Pett S.B., Alonso D., Richter R.C., Stelzer P., Subrazmanian V., Tack Goldman K., Gay W.A. Jr. Differential inhibition by aspirin of vascular and platelet prostaglandin synthesis in atherosclerotic patients. N Engl J Med. 308:1983;800-805.
8. Patrono C., Ciabattoni G., Patrignani P., Pugliese F., Filabozzi P., Catella F., Davi' G. Forni L. Clinical pharmacology of platelet cyclooxygenase inhibition. Circulation. 72:1985;1177-1184.
9. The Dutch Tia Trial Study Group A comparison of two doses of aspirin (30 mg vs. 283 mg a day) in patients after a transient ischemic attack or minor ischemic stroke. N Engl J Med. 325:1991;1261-1266.
10. Bjornsson T.D., Schneider D.E., Berger H. Jr. Aspirin acetylates fibrinogen and enhances fibrinolysis. Fibrinolytic effect is independent of changes in plasminogen activator levels J Pharmacol Exp Ther. 250:1989;154-161.
11. Ratnatunga C.P., Edmondson S.F., Rees G.M., Kovacs I.B. High-dose aspirin inhibits shear-induced platelet reaction involvi ng thrombin generation. Circulation. 85:1992;1077-1082.
12. Szczeklik A., Krzanowski M., Gora P., Radwan J. Antiplatelet drugs and generation of thrombin in clotting blood. Blood. 80:1992;2006-2011.
13. Funk C.D., Funk L.B., Kennedy M.E., Pong A.S., Fitzgerald G.A. Human platelet/erythroleukemia cell prostaglandin G/H synt hase. cDNA cloning, expression, mutagenesis and gene chromosomal assignment FASEB J. 5:1991;2304-2312.
14. Hamberg M., Svensson J., Samuelsson B. Thromboxanes. A new group of biologically active compounds derived from prostaglandin endoperoxides Proc Natl Acad Sci USA. 72:1975;2294-2298.
15. Fitzgerald G.A. Mechanisms of platelet activation. thromboxane A2 as an amplifying signal for other agonists Am J Cardiol. 68:1991;11B-15B.
16. Fitzgerald D.J., Roy L., Catella F., Fitzgerald G.A. Platelet activation in unstable coronary disease. N Engl J Med. 315:1986;983-989.
17. Koustaal P.J., Ciabattoni G., Van Gun J., Nieuwenhuis H.K., De Groot P.G., Sixma J.J., Patrono C. Increased thromboxane biosynthesis in patients with acute cerebral ischemia. Stroke. 24:1993;219-223.
18. Van Kooten F., Ciabattoni G., Patrono C., Dippel D.W.J., Koustaal P.J. Platelet activation and lipid peroxidation in patients with acute ischemic stroke. Stroke. 28:1997;1557-1563.
19. Davi' G., Gresele P., Violi F., Basili S., Catalano M., Giammarresi C., Volpato R., Nenci G.G., Ciabattoni G., Patrono C. Diabetes mellitus, hypercholesterolemia and hypertension, but not vascular per se, are associated with persistent platelet activation in vivo. Evidence derived from the study of peripheral arterial disease. Circulation. 78:1997;617-621.
20. Willard J.E., Lange R.A., Hillis L.D. The use of aspirin in ischemic heart disease. N Engl J Med. 327:1992;175-181.
21. Sherman D.G., Dyken M.L. Jr., Gent M., Harrison M.J.G., Hart R.G., Mohr J.P. Antithrombotic therapy for cerebrovascular disorders. Chest. 108:1995;444S-456S.
22. Barnett H.J.M., Eliasziw M., Meldrum H.E. Drugs and surgery in the prevention of ischemic stroke. N Engl J Med. 332:1995;238-248.
23. Barnett H.J.M., Kaste M., Meldrum H., Eliasziw M. Aspirin dose in stroke prevention. Beautiful hypotheses slain by ugly facts Stroke. 27:1996;588-592.
24. Helgason C.M., Hoff J.A., Kondos G.T., Brace L.D. Platelet aggregation in patients with atrial fibrillation taking aspirin or warfarin. Stroke. 24:1993;1458-1461.
25. Helgason C.M., Bolin K.M., Hoff J.A., Winkler S.R., Mamgat A., Tortorice K.L., Brace L.D. Development of aspirin resistance in persons with previous ischemic stroke. Stroke. 25:1994;2331-2336.
26. Komiya T., Kudo M., Urabe T., Mizuno Y. Compliance with antiplatelet therapy in patients with ischemic cerebrovascular disease. Stroke. 25:1994;2337-2342.
27. Vejar M., Fragasso G., Hackett D., Lipkin P.D., Maseri A., Born G.V.R., Ciabattoni G., Patrono C. Dissociation of platelet activation and spontaneous myocardial ischemia in unstable angina. Thromb Haemostas. 63:1990;163-168.
28. Patrignani P., Panara M.R., Greco A., Fusco O., Natoli C., Iacobelli S., Cipollone F., Ganci A., Creminon C., Maclouf J., Patrono C. Biochemical and pharmacological characterization of the cyclooxygenase activity of human blood prostaglandin endoperoxide synthases. J Pharmacol Exp Ther. 271:1994;1705-1712.
29. Cipollone F., Patrignani P., Greco A., Panara M.R., Padovano R., Cuccurullo F., Patrano C., Rebuzzi A.G., Liuzzo G., Quaranta G., Maseri A. Differential suppression of thromboxane biosynthesis by indobufen and aspirin in patients with unstable angina. Circulation. 96:1997;1109-1116.
30. The Salt Collaborative Group Swedish Aspirin Low-dose Trial (SALT) of 75 mg aspirin as secondary prophylaxis after cerebrovascular ischemic events. Lancet. 338:1991;1345-1349.
31. Gent M., Blakely J.A., Easton J.D., Ellis D.J., Hachinski V.C., Harbison J.W., Panak E., Roberts R.S., Sicurella J., Turpie A.G.G., The CATS Group The Canadian American Ticlopidine Study (CATS) in thromboembolic stroke. Lancet. 1:1989;1215-1220.
32. ESPS Group European Stroke Prevention Study. Stroke. 21:1990;1122-1130.
33. Bousser M.G., Eschwege E., Haguenau M., Lefauconier J.M., Thibuet N., Toubul D., Toubul P.J. "AICLA" controlled trial of aspirin and dipyridamole in the secondary prevention of athero-thrombotic cerebral ischemia. Stroke. 14:1983;5-14.
34. The Canadian Cooperative Study Group A randomized trial of aspirin and sulfinpyrazone in threatened stroke. N Engl J Med. 299:1978;53-59.
35. Diener H.C., Cunha L., Forbes C., Sivenius J., Smets P., Lowenthal A. European Stroke Prevention Study 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci. 143:1996;1-3.
36. CAPRIE Steering Committee A randomised, blinded trial of clopidogrel versus aspirin in patients at risk of ischaemic events. Lancet. 348:1996;1329-1339.
37. International Stroke Trial Collaborative Group The International Stroke Trial (IST). A randomised trial of aspirin, subcutaneous heparin, both, or neither among 19,435 patients with acute ischaemic stroke Lancet. 349:1997;1569-1581.
38. CAST (Chinese Acute Stroke Trial) Collaborative Group CAST. Randomised placebo-controlled trial of early aspirin use in 20,000 patients with acute ischemic stroke Lancet. 349:1997;1647-1649.
39. Van Kooten F., Ciabattoni G., Patrono C., Schmitz P.I.M., Van Gijn J., Koudstaal P.J. Evidence for episodic platelet activation in acute ischemic stroke. Stroke. 25:1994;278-281.
40. The Stoke Prevention in Reversible Ischemia Trial (SPIRIT) Study Group A randomized trial of anticoagulants versus aspirin after cerebral ischemia of presumed arterial origin. Ann Neurol. 42:1997;857-865.